Apixaban: an emerging oral factor Xa inhibitor
C Roser-Jones, RC Becker - 2010 - Springer
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …
the prevention and treatment of thromboembolic diseases. In comparison with current …
Apixaban: an emerging oral factor Xa inhibitor
C Roser-Jones, RC Becker - Journal of Thrombosis and Thrombolysis, 2010 - infona.pl
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …
the prevention and treatment of thromboembolic diseases. In comparison with current …
Apixaban: an emerging oral factor Xa inhibitor
C Roser-jones, RC Becker - Journal of Thrombosis and …, 2010 - search.proquest.com
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …
the prevention and treatment of thromboembolic diseases. In comparison with current …
Apixaban: an emerging oral factor Xa inhibitor
C Roser-Jones, RC Becker - Journal of thrombosis and …, 2010 - pubmed.ncbi.nlm.nih.gov
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …
the prevention and treatment of thromboembolic diseases. In comparison with current …
Apixaban: an emerging oral factor Xa inhibitor.
C Roser-Jones, RC Becker - Journal of Thrombosis and …, 2010 - europepmc.org
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …
the prevention and treatment of thromboembolic diseases. In comparison with current …